Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.61 - $65.53
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.31M
Market Cap
$7.37B
Enterprise Value$8.29B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.8
Beta1.18
Next Earnings
May 13, 2025EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.43
Shares Outstanding123,153,000
10 Day Avg. Volume1,243,138
30 Day Avg. Volume1,308,464
Standard Deviation0.13
R-Squared0.27
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.76
Price to Cash Flow (P/CF)15.90
P/FCF Ratio16.10
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.68
Enterprise Value/Ebitda14.53
Forecast
1Y Price Target
$66.11Price Target Upside14.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ4 EPS of $1.06 beat estimates, driven by strong royalty revenues and cost discipline.
Product SuccessThe main drivers for the company's royalty revenue growth for 4Q24 were the continued commercial success of DARZALEX Faspro and Phesgo and early growth of VYVGART Hytrulo for treatment of generalized myasthenia gravis.
Bears Say
Future Revenue ChallengesInvestors should note that collaboration revenue is expected to decrease in 2025 due to the change in expectations for the approval timeline for amivantamab.
---
Ownership Overview
0.98% Insiders
30.85% Mutual Funds
22.98% Other Institutional Investors
14.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $36.61 and its highest was $65.53 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $7.37B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 80 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 18, 2025. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.158 by $0.102.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 0.96.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 123,153,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.26 in its last earnings report, beating expectations of $1.158. Following the earnings report the stock price went down -0.225%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.11 (14.48% Upside)
$66.11 (14.48% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.55%
12-Months-Change
Fundamentals
Return on Equity
198.42%
Trailing 12-Months
Asset Growth
24.84%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
HALO Company Deck
---
HALO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with record-breaking revenue, strong growth in key products, and an optimistic outlook for 2025 and beyond. While there were some setbacks, such as the delay in Amivantamab subcutaneous approval and temporary royalty rate impacts, these were overshadowed by the overall strong financial performance and strategic achievements.Read More>---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$66.11
▲(14.48% Upside)
Technical Analysis
Best Analysts Covering HALO
1 Year
1 Year Success Rate
17/19 ratings generated profit
1 Year Average Return
+24.49%
reiterated a buy rating 5 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +24.49% per trade.
---